Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 93 publications
D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.
Journal: Leukemia & lymphoma
Published: June 26, 2026
A Simplified Frailty Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: May 18, 2026
Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.
Journal: British journal of haematology
Published: May 14, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.
Journal: Transplantation and cellular therapy
Published: March 26, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.
Journal: British journal of haematology
Published: March 13, 2026
D-VRD induction and autologous transplant in patients ≥70 years.
Journal: Blood cancer journal
Published: February 12, 2026
Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation.
Journal: Leukemia & lymphoma
Published: January 29, 2026
Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance.
Journal: Clinical lymphoma, myeloma & leukemia
Published: November 14, 2025
Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis.
Journal: Transplantation and cellular therapy
Published: November 10, 2025
Last Updated: 09/26/2026